EFFECTS OF LONG-TERM ESTROGEN THERAPY ON SERUM CHOLESTEROL AND PHOSPHOLIPIDS IN MEN WITH MYOCARDIAL INFARCTION
Authors: J MARMORSTON, F J MOORE, O MAGIDSON, O KUZMA, J J LEWIS
Journal: Annals of Internal Medicine (1959)

Article1 November 1959EFFECTS OF LONG-TERM ESTROGEN THERAPY ON SERUM CHOLESTEROL AND PHOSPHOLIPIDS IN MEN WITH MYOCARDIAL INFARCTIONJESSIE MARMORSTON, M.D., FREDERICK J. MOORE, M.D., OSCAR MAGIDSON, M.D., OLIVER KUZMA, M.D., JACK J. LEWIS, M.D.JESSIE MARMORSTON, M.D.Search for more papers by this author, FREDERICK J. MOORE, M.D.Search for more papers by this author, OSCAR MAGIDSON, M.D.Search for more papers by this author, OLIVER KUZMA, M.D.Search for more papers by this author, JACK J. LEWIS, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-51-5-972 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt has been well established1-8 that administration of estrogen to men or women with myocardial infarction tends to raise the serum phospholipids and to lower the serum cholesterol and the cholesterol/phospholipid (C/P) ratio. In a recent communication9 we noted that prolonged administration of ethinyl estradiol to postmenopausal women with myocardial infarction resulted in changes in these serum lipids, chiefly in those in whom the levels were initially abnormal. Thus estrogen therapy in effect tended to bring these serum lipids to "normal" levels.We wish to report here the effects upon cholesterol and phospholipids of long-term estrogen therapy, using clinically well...Bibliography1. Eilert ML: Effects of estrogens upon partition of serum lipids in female patients, Am. Heart J. 38: 472, 1949. Google Scholar2. StamlerPickKatz JRLN: Experiences in assessing estrogen antiatherogenesis in chick, rabbit and man, Ann. New York Acad. Sc. 64: 596-619, 1956. CrossrefMedlineGoogle Scholar3. RussEderBarr EMHADP: Influence of gonadal hormones on proteinlipid relationship in human plasma, Am. J. Med. 19: 4-24, 1955. CrossrefMedlineGoogle Scholar4. SteinerPaysonKendall AHFH: Effects of estrogenic hormones on serum lipids in patients with coronary arteriosclerosis, Circulation 11: 784-788, 1955. CrossrefMedlineGoogle Scholar5. OliverBoyd MFGS: Influence of sex hormones on circulating lipids and lipoproteins in coronary sclerosis, Circulation 13: 82-91, 1956. CrossrefMedlineGoogle Scholar6. RobinsonHiganoCohenSniffenSherer RWNWDRCJW: Effects of estrogen therapy on hormonal functions and serum lipids in men with coronary atherosclerosis, Circulation 14: 365, 1956. CrossrefMedlineGoogle Scholar7. Eilert HL: Effect of estrogens on partition of serum lipids in female patients, Metabolism 2: 137-145, 1953. MedlineGoogle Scholar8. CohenHiganoRobinson WDNRW: Serum lipid and estrogenic effects of Manvene, a new estrogen analogue, Circulation 17: 1035-1040, 1958. CrossrefMedlineGoogle Scholar9. MarmorstonMagidsonLewisMehlMooreBernstein JOJJJFJJ: Effect of small doses of estrogen on serum lipids in female patients with myocardial infarction, New England J. Med. 258: 583-586, 1958. CrossrefMedlineGoogle Scholar10. PearsonSternMcGavack SSTH: Rapid, accurate method for determination of total cholesterol in serum, Anal. Chem. 25: 813, 1953. CrossrefGoogle Scholar11. LowryRobertsLeinerWuFarr OHNRKYMAL: Quantitative histochemistry of brain; chemical methods, J. Biol. Chem. 207: 1-17, 1954. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Los Angeles, California*Received for publication February 25, 1959.Read at the Regional Meeting of The American College of Physicians, Palm Springs, California, February 7-8, 1959.From the Departments of Medicine and Public Health, University of Southern California School of Medicine, the Los Angeles County Hospital and the Cedars of Lebanon Hospital.†Aided by grants from the Albert and Mary Lasker Foundation, and grants H-2198, H-2199 and H-2701 from the National Heart Institute.We are indebted to Dr. Kenneth Ericson, of Organon, Inc., for supplies of Lynoral (ethinyl estradiol), to Dr. Irwin C. Winter, of G. D. Searle and Co., for Manvene (SC 6924, 3 methoxy-16α-methyl-1,3,5(10)-estriene-16β,17β-diol), and to Dr. John J. Jewell, of the Ayerst Laboratories, for Premarin (mixed conjugated equine estrogens NNR), used in these studies.Requests for reprints should be addressed to Jessie Marmorston, M.D., 613 North Canon Drive, Beverly Hills, California. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byRelationship of Estrogen Therapy for Carcinoma of the Prostate to Atherosclerotic Cardiovascular Disease: A Clinicopathologic StudyBiological Properties of Estrogen SulfatesARE GONADAL HORMONES (ESTROGENS AND ANDROGENS) OF SIGNIFICANCE IN THE DEVELOPMENT OF ISCHEMIC HEART DISEASE?The interrelationship of blood lipids and estrogensEfficacy of Drugs in Lowering Blood CholesterolGonadal Hormones and Lipid MetabolismSteroids and Lipid MetabolismPractical significance of serum triglycerides and radioactive fat toleranceTREATMENT OF DIABETIC RETINOPATHY WITH ESTROGENSORAL AND INTRAVENOUS ESTROGENS IN THE TREATMENT AND PREVENTION OF BLEEDING ASSOCIATED WITH LONG-TERM ANTICOAGULANT THERAPY 1 November 1959Volume 51, Issue 5Page: 972-982KeywordsCholesterolElectrocardiographyEstradiolEstrogensHeartHospital medicineLipidsMyocardial infarctionPhospholipidsPrevention, policy, and public health ePublished: 1 December 2008 Issue Published: 1 November 1959 PDF downloadLoading ...